Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio [Yahoo! Finance]
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Yahoo! Finance
addition of Cidara Therapeutics Inc ( NASDAQ:CDTX ). On December 31, 2023, Point72 acquired 1,250,228 shares of the biotechnology company, reflecting a new position in the firm's diverse investment landscape. The transaction was executed at a trade price of $0.794 per share, marking a strategic move by one of the industry's leading investment entities. Profile of the Investment Firm: Steven Cohen Trades Portfolio )'s Point72 Warning! GuruFocus has detected 5 Warning Signs with CDTX. Steven A. Cohen stands at the helm of Point72 as its Chairman and CEO, overseeing a robust team of over 1,650 professionals. The firm, which evolved from S.A.C. Capital Advisors, operates as a registered investment advisor since 2014. Cohen's investment philosophy centers around a long/short equity strategy, employing a fundamental bottom-up research process to drive macro investments and insights. With top holdings in technology and healthcare sectors, including giants like Amazon.com Inc ( NASDAQ:A
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Cidara Therapeutics: Now Well-Funded To Advance Its Cloudbreak Platform [Seeking Alpha]Seeking Alpha
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 [Yahoo! Finance]Yahoo! Finance
- Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024GlobeNewswire
- CIDARA Therapeutics ALERT: Bragar Eagel & Squire, P.C. is Investigating Cidara Therapeutics, Inc. on Behalf of Cidara Therapeutics Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- Cidara Therapeutics, Inc. (NASDAQ: CDTX) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $40.00 price target on the stock.MarketBeat
CDTX
Earnings
- 11/2/23 - Beat
CDTX
Sec Filings
- 4/24/24 - Form 8-K
- 4/24/24 - Form 8-K
- 4/23/24 - Form S-8
- CDTX's page on the SEC website